Evaluation of Fluctuations of Gene Expression and its Polymorphism at rs1267623 in Colorectal Cancer.

BACKGROUND

Molecular markers in Colorectal Cancer (CRC) are needed for more accurate classification and personalized treatment. In this way, we investigated the effects of the gene on clinical outcomes of its expression fluctuations and its polymorphism at rs1267623 in CRC.

METHODS

In this study, 36.36 percent of patients with CRC were women, and 63.63 percent were men. After the pathology department confirmed the tumor of the samples, the stage and grade of the tumor were determined according to the TNM system. Real-time PCR was used to check the expression of the gene in tumor and non-tumor tissues, and its polymorphism in rs1267623 was also checked using the Tetra-ARMs PCR technique.

RESULTS

The expression of in tumor tissues was significantly higher than in non-tumoral tissues (P = 0.001), indicating an upregulation of gene expression in tumoral tissues. The user's text is empty. Furthermore, there was a significant correlation between expression and tumor stage ( = 0.001), as well as tumor grade ( = 0.003). However, no significant link was found between lymph node metastasis and distant metastasis of gene expression ( = 0.3). Additionally, no mutation was detected in the investigation of rs1267623 polymorphism.

CONCLUSION

The gene was upregulated in tumoral tissues. Remarkably, no mutation was found in the rs1267623 polymorphism. As a result, this gene can be used as a biomarker in the diagnosis and treatment of CRC.